Jacob Chacko, MD has joined Bonti’s Board of Directors.

Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications, Facility Operations, and IT, and has helped lead over $500 million in capital raises. He was part of the management team that helped guide the company through the successful acquisition by Roche in December 2017.

He is succeeding director David Ramsay, who has been a long-standing director of Bonti since 2015 and is making a planned transition from the Board to the company management as Chief Financial Officer.

Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, a global private investment firm with approximately $75 billion of assets under management, where he helped lead teams that successfully completed acquisitions having an aggregate value of over $10 billion. He served on the boards of directors of RentPath and EnvisionRx, was an advisor to the audit committee of Par Pharmaceutical and was a board observer to IMS Health and Quintiles Transnational. Dr. Chacko currently serves as the Chairperson of the Western Regional Selection Committee for the Marshall Scholarship.

“The experience of the Bonti management team in the neurotoxin field along with a steadily advancing clinical pipeline positions the company well for future success,” says Dr. Chacko in a news release.  “I look forward to working closely with the board and management team in advancing Bonti’s novel treatment paradigms to address unmet therapeutic and medical aesthetic needs of millions of patients.”

Bonti's lead product candidate, EEB- 001, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized by fast onset of action (within 24 hours) and a short duration of effect (about 4 weeks).